A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis

SR-878 is a newly developed medicine that aims to treat autoimmune disorders. It inhibits a protein (iRhom2), that regulates enzymes that are involved in the production of cytokines (small proteins that are crucial in controlling the activity of immune system cells). The aim of this clinical trial is to find a suitable safe and effective SR-878 dose for patients with rheumatoid arthritis. The study will include a screening period, an inpatient treatment period, and an outpatient follow-up period. The study duration for an individual participant is up to 113 days (about 16 weeks).

NCT Number	NCT07433335
Lead Sponsor	SciRhom GmbH Collaborators: FGK Clinical Research GmbH
Conditions	Rheumatoid Arthritis
Enrollment	27 participants
Start Date	2026-04-07
Primary Completion	2028-02-29 (estimated)
Study Completion	2028-02-29 (estimated)
Updated on ClinicalTrials.gov	2026-05-11